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Tunable controlled release of bioactive SDF-1a
via specific protein interactions within
fibrin/nanoparticle composites†
D. Dutta, C. Fauer, H. L. Mulleneux and S. E. Stabenfeldt*
The chemokine, stromal cell-derived factor 1a (SDF-1a), is a key regulator of the endogenous neural
progenitor/stem cell-mediated regenerative response after neural injury. Increased and sustained
bioavailability of SDF-1a in the peri-injury region is hypothesized to modulate this endogenous repair
response. Here, we describe poly(lactic-co-glycolic) acid (PLGA) nanoparticles capable of releasing
bioactive SDF-1a in a sustained manner over 60 days after a burst of 23%. Moreover, we report a
biphasic cellular response to SDF-1a concentrations thus the large initial burst release in an in vivo
setting may result in supratherapeutic concentrations of SDF-1a. Specific protein–protein interactions
between SDF-1a and fibrin (as well as its monomer, fibrinogen) were exploited to control the magnitude
of the burst release. Nanoparticles embedded in fibrin significantly reduced the amount of SDF-1a
released after 72 h as a function of fibrin density. Therefore, the nanoparticle/fibrin composites
represented a means to independently tune the magnitude of the burst phase release from the
nanoparticles while perserving a bioactive depot of SDF-1a for release over 60 days.
1. Introduction
Traumatic brain injury (TBI) is a leading cause of death and
disability around the world with over 50 000 deaths and an
estimated $60 billion in direct and indirect economic costs
every year, in the United States alone.1 Although current treat-
ment practices have demonstrated some efficacy in treating its
long-term effects, there are no means of directly addressing
the underlying pathophysiology of TBI.2 Recent studies have
reported the activation of endogenous neural progenitor/stem
cell (NPSC)-mediated neurotrophic support and neurogenesis
after injury events (e.g. stroke or traumatic brain injury).3–5
NPSCs originating from the two adult neural stem cell niches
(subventricular zone, SVZ; and subgranular zone of hippo-
campus dentate gyrus) selectively migrate to the injury penumbra
forming ectopic niches, even within non-neurogenic areas of the
brain (such as adult cortical tissues).4,6 The concentration of
the chemokine, stromal cell-derived factor-1a (SDF-1a), and the
expression of its receptor, CXCR4, increases significantly in the
injury penumbra and is implicated as a key regulator of directed
NPSC recruitment after neural injury.3,4 However, increased
SDF-1a levels subside by 14 days post injury, in most reports,
coinciding with a diminishing number of NPSCs (observed at
the injured area).3,4,7,8 Building on this inherent injury-
stimulated signal, we postulate that increased and sustained
bioavailability of SDF-1a locally in the injury penumbra would
augment NPSC recruitment and bolster the capacity for endo-
genous regeneration.
With this in vivo application in mind, this study focused on
developing a drug delivery device for local, sustained release of
SDF-1a with the following attributes: (1) injectable, (2) bio-
degradable, (3) prolonged release well past 14 days and (4) main-
tenance of SDF-1a levels within the therapeutic concentration
range. The most basic form of delivering therapeutics is systemic
bolus administration. Drawbacks of this method include a lack
of control over biodistribution due to physiological barriers (i.e.
endothelial barrier) and rapid systemic clearance.3 Direct, local
injection in the target tissue affords control over dosage, but
negates temporal control or payload degradation leading to only
transient therapeutic benefits. Conventional means for local,
sustained delivery to control both dosage and temporal concen-
tration profile involve bulky, invasive minipump systems that are
linked to infections, bleeding and neurologic injury.9 Injectable
biomaterials for the controlled release of therapeutics (i.e. hydro-
gels and biodegradable plastics) hold the capacity to overcome the
common limitations of drug delivery (i.e. dosage, temporal concen-
tration, biocompatibility & patient compliance).10 Release devices
for local and sustained delivery of SDF-1a have been explored
in several different physiological applications including neural
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regeneration, myocardial infarctions, skeletal regeneration and
wound healing.11–14 However, many of these previous designs
were based on hydrogels (such as, alginate, collagen, gelatin,
star PEG–heparin etc.) and provided sustained SDF-1a for less
than 14 days. Therefore, we sought to tailor a controlled release
system that fits the aforementioned design criterion, ultimately
for neural applications.
Poly(lactic-co-glycolic) acid (PLGA), a FDA-approved bio-
degradable polyester, has long been studied for diverse applica-
tions in the central nervous system.15,16 In addition tunable
release profiles, a significant benefit of PLGA carriers is insula-
tion of encapsulated cargo from the local microenvironment,
limiting specific and non-specific degradation and leading to
increased protein half-life.17 With a half-life of 25 min in blood,
maintaining SDF-1a bioactivity was an important parameter for
this study.18 Sustained delivery of SDF-1a has been achieved
with macro-scale PLGA scaffolds and microparticles.19–21 Yet,
the utility of such macro-to-micro-scale systems for minimally
invasive delivery is limited. As such, novel nanoscale SDF-1a
PLGA-based devices are of great interest.
The release profiles of encapsulated cargo from PLGA-based
particles vary greatly (zero-order, monophasic, biphasic and
triphasic) depending primarily on formulation parameters and
typically includes a burst release within the first few hours.22
The PLGA burst phase is problematic since supra-therapeutic
concentrations may result in undesired biological consequences.
Mechanisms to address the burst issue range multilayer coatings
to composite system embedding PLGA particles within hydrogel
matrices. The biologically-derived matrix fibrin has been investi-
gated as a carrier for protein delivery.23,24 Numerous studies report
engineered fibrin-derivatives crosslinkers to mediate and enhance
affinity-based interactions for controlled release of a multitude of
biologics (e.g. nerve growth factor (NGF), neurotrophin-3, glial-
derived neurotrophic factor, genetic material).25–28 As a natural
extracellular matrix (ECM) protein, fibrin possesses inherent ability
to bind and sequester soluble signaling factors, predominately
through a heparin-like binding domains that mediate immobiliza-
tion of small, highly basic (and heparin-binding) proteins such as
basic fibroblast growth factor (bFGF).29–31 Here in this study, we
hypothesized that embedding SDF-1a-loaded NPs within fibrin
matrices will modulate the burst release phase due to specific
protein–protein interactions between SDF-1a and fibrin. The key
objectives for this study were to (1) characterize SDF-1a-loaded NPs,
(2) probe the mechanism of SDF-1a/fibrin(ogen) interactions and
(3) determine the effect of SDF-1a/fibrin(ogen) interactions on SDF-
1a release from PLGA NPs. Collectively, we report a composite
fibrin/PLGA systemwith the capacity to achieve long-term (60 days),
bioactive SDF-1a release and the means to independently tune
protein release during the burst phase.
2. Methods and materials
2.1 Materials
Poly(lactic-co-glycolic) acid (PLGA; 50 : 50 ester-terminated;
inherent viscosity = 0.55–0.75 dL g1) was purchased from
Lactel (Birmingham, USA). Recombinant mouse stromal cell-
derived factor-1a (SDF-1a) was acquired from PeproTech (Rocky
Hill, USA). B27 growth supplement, DAPI nuclear stain, tetra-
methylbenzidine (TMB) substrate and Dulbecco’s modified
eagle medium were acquired from Life Technologies (Carlsbad,
USA). Glucose was obtained from Acros Organics (Geel, Belgium).
High-binding 96-well enzyme-linked immunosorbent assay
(ELISA) plates were acquired fromGreiner Bio-One (Frickenhausen,
Germany). The organic solvent ethyl acetate was acquired from Alfa
Aesar (Ward Hill, USA) and dimethyl sulfoxide (DMSO) from
American bioanalytical (Natick, USA). Human fibrinogen (Plasmi-
nogen, von Willebrand Factor and Fibronectin Depleted), human
a-thrombin, human factor XIIIa (FXIII) and human plasmin were
acquired from Enzyme Research Laboratories (South Bend, USA).
All other materials and chemicals were purchased from Sigma-
Aldrich (St. Louis, USA) and used without further modification or
purification.
2.2 Synthesis of SDF-1a loaded nanoparticles
SDF-1a loaded PLGA nanoparticles were synthesized using a
water/oil/water (W/O/W) emulsion technique adapted from
a previously published protocol.32 Briefly, the first emulsion
(W/O) was obtained by vortexing the oil phase (100 mg mL1
PLGA in ethyl acetate) with PBS buffer solution (pH = 7.4)
containing 20.0 mg mL1 bovine serum albumin (BSA; 2.0%
w/w of PLGA) and 2.0 mg mL1 SDF-1a (0.2% w/w of PLGA). The
above solution was added dropwise to a 3.6 volume excess of
an aqueous 5.0% (w/v) D-a-tocopheryl polyethylene glycol 1000
succinate (TPGS) and the second emulsion (W/O/W) was pro-
duced by ultrasonicating (Omni Ruptor 4000; Omni Interna-
tional; Kennesaw, USA) the solution for two consecutive 15 s
periods in an ice bath (120 W power with a 90% duty cycle). The
emulsion was then quickly transferred to a stirring (300 RPM)
aqueous bath containing 0.5% TPGS + 1.25% (w/v) NaCl
(10 volume excess) and left undisturbed for 3 h for solvent
evaporation. The particle suspension was washed three times
with deionized water by centrifugation at 15 000g for 15 min in
between rinses (Beckman Counter; Allegra 25R; Pasadena, USA).
The particles were supplemented with 25% (w/w) D-(+)-trehalose
dihydrate and recovered through lyophilization. Particle size
analyses were performed by scanning electron microscope
(SEM; Phillips XL-30; San Francisco, USA) using a 3–5 kV electron
beam. Lyophilized particle samples were prepared for SEM
analysis via gold/palladium sputter coater (108-Auto, Cressington
Scientific; Watford, UK) to achieve a 5–10 nm thick layer.
A minimum of 7 images were captured per group and were
processed using ImageJ to determine the size distributions. At
least 85 sampling points were required for each image and thus
size distribution histograms are comprised of a minimum of
595 measurement points in total.
2.3 Protein loading & release assays
Total protein loading was determined by complete dissolution
of a known amount of particles (10 mg mL1) in dimethyl
sulfoxide (DMSO). The DMSO solution was then diluted 1 : 15
using 2.5% (w/v) sodium dodecyl sulfate and 0.1 N NaOH in
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deionized water. The mixture was thoroughly agitated, being
careful not to introduce bubbles. Known amounts of soluble
BSA added to blank particles (no protein encapsulated; synthe-
sized using identical synthesis protocols) were used to generate
calibration curve. Protein quantification was performed using
bicinchoninic assay (BCA; G Biosciences; St. Louis, USA) in
triplicates following manufacturer’s protocols. Encapsulation
efficiency and loading capacity were calculated using the
following:
Encapsulation efficiency ð%Þ
¼ 100 Total encapsulated protein ðmgÞ
Total protein added ðmgÞ
 
Loading capacity ð%Þ ¼ 100 SDF content in NPs ðmgÞ
Amount of NPs ðmgÞ
 
For the release assays, lyophilized particles were resuspended
in 1 mL of buffer release media (1 PBS supplemented with
0.01% tween 80 and 0.01% NaN3) at 3.5 mg mL
1 and incubated
at 37 1C under constant agitation. At specified time points, the
supernatant was collected by centrifuging the particle suspen-
sion at 14000g for 15 min, collecting 90% of the supernatant and
replenishing with fresh buffer release media. Extracted buffer
release media samples were stored at 80 1C for subsequent
protein analysis. To specifically determine the SDF-1a content, a
known concentration (500 ng mL1) was incubated alongside
the NP suspension as a positive control for subsequent analysis
using ELISA-based detection (R&D systems; Minneapolis, USA).
NPs with no encapsulated SDF-1a served as the negative control.
2.4 SDF-1a bioactivity assay
2.4.1 Neural progenitor/stem cell harvest and culture.Murine
fetal derived neural/progenitor stem cells (NPSCs) were isolated
from the medial and lateral germinal eminences of E14.5 C57BL/
6 mice based on previously published protocols and in accordance
with approval by the Institutional Animal Care and Use Committee
at Arizona State University.33 The germinal eminences were
harvested, mechanically disassociated and cultured in NPSC
medium (Dulbecco’s modified eagle medium (DMEM:F12) with
2.4 mg mL1 sodium bicarbonate (NaHCO3), 6 mg mL
1
glucose, 5 mM HEPES, 62.9 ng mL1 progesterone, 9.6 mg mL1
putrescine, 1.83 mg mL1 heparin, 1 B27 growth supplement,
20 ng mL1 epidermal growth factor (EGF), 5 ng mL1 bFGF,
5 mg mL1 insulin, 5 mg mL1 transferrin, and 5 ng mL1 sodium
selenite). NPSCs were cultured as non-adherent neurospheres and
used for experimentation between passages 3–6.
2.4.2 Modified Boyden chamber assay. NPSC chemotaxis
in a modified-Boyden chamber assay was used to determine
SDF-1a bioactivity as previously described.34 In short, disasso-
ciated NPSCs were plated (70 000 cells per cm2) on laminin-
coated transwell inserts with 12 mm pore diameter (Millipore,
Temecula, CA). Growth factor-free NPSC medium (no EGF or
bFGF) with 0 or 250 ngmL1 SDF-1a (negative and positive control,
respectively) was added in the bottom chamber. NPSCs were then
allowed to undergo chemotaxis for 24 h in an incubator (37 1C
and 5% CO2). Subsequently, cells on the top side of the transwell
membrane were removed using a cotton swab whereas migrated
cells that reached the bottom were fixed, underwent a DAPI
nuclear stain and imaged. NPSC nuclei have diameters of
approximately 20 mm.35 After intensity thresholding, nuclei
count was quantified using a particle count algorithm in ImageJ
where stained nuclei 10–30 mm in diameter were counted as
individual cells (Fig. S1 and S2, ESI†). Nuclei count was deter-
mined by imaging and quantifying whole transwell membranes.
2.4.3 Bioactivity of encapsulated SDF-1a. The bioactivity
of the encapsulated/released SDF-1a from PLGA NPs was eval-
uated at two time point intervals (day 0–1 and day 20–22) via the
modified Boyden chamber assay described above. Release
samples were acquired from blank and SDF-1a-loaded NPs
resuspended in cell culture release media (DMEM:F12 supple-
mented with 2.4 mg mL1 NaHCO3); the NP concentration for
day 0–1 interval was 9.0 mg mL1 versus 17.5 mg mL1 for day
20–22 to account for variation in the amount of SDF-1a released
during the burst or sustained release phases. The NP suspen-
sions were incubated at 37 1C with agitation, taking precautions
to maintain sterility. For the day 20–22 interval, the cell culture
release media was exchanged every 3 days until day 20. After the
specified incubation period, NPs were centrifuged (14 000g for
15 min) to collect the supernatant, and the modified Boyden
chamber assay was carried out immediately. NP cell culture
release media was diluted 1 : 10 and 1 : 2 for day 0–1 and day 20–22
samples, respectively, with growth factor-free NPSC media to
achieve a SDF-1a concentration in the NPSC chemotactic range
(Fig. 2). The dilution factors were estimated via a preliminary total
protein release profile (data not shown). A minimum of 4 replicates
per group performed for all migration assays.
2.5 SDF-1a-fibrin(ogen) binding detection ELISAs
SDF-1a-fibrinogen interaction were probed by adapting a pre-
viously described modified ELISA.30 SDF-1a, BSA and basic
fibroblast growth factor (bFGF) were coated on high-binding
ELISA plates by incubating the soluble factors at 100 nM (in
100 mM carbonate buffer; pH 9.6) for 3 h at 37 1C. All growth
factor (GF) coated wells were blocked using 2.0% (w/v) fat-free
powdered milk in PBS for 1 h at room temperature (RT).
Fibrinogen (35 mg mL1; depleted of fibronectin, plasminogen,
and von Willebrand factor) was incubated for 1 h at RT. The
primary antibody (rabbit anti-fibrinogen; EMD Millipore;
Darmstadt, Germany) was then added for 1 h at RT, followed
by the secondary antibody (HRP conjugated goat anti-rabbit
IgG; Thermo Scientific; Waltham, USA), also under the same
conditions. Detection was carried out TMB substrate following
manufacturer’s protocols. Four washes were performed in
between each of the steps mentioned using PBS with 0.01%
Tween-20 (PBS-T). Heparin competition ELISAs were also per-
formed with various concentrations (0.75–200 mg mL1) of
soluble heparin (17–19 kDa), which was supplemented in the
fibrinogen solution after the blocking step mentioned above.30
All subsequent steps were kept identical.
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The next modified ELISA probed SDF-1a interactions with
fibrin. A previously described protocol was adapted to generate
a thin layer of fibrin network on high-binding ELISA plates.36 In
short, fibrinogen (depleted of fibronectin, plasminogen, and
von Willebrand factor) was incubated at 100 mg mL1 for 1 h at
RT. After rinsing three times with Tris-buffered solution
(10 mM Tris + 150 mM NaCl), the wells were blocked using
1.0% (w/v) BSA for 20 min at RT. After rinsing, human thrombin
(2.5 NIH U mL1) and human FXIIIa (0.5 NIH U mL1) was
added and incubated for 15 min at RT. Fibrin coating was
completed after washing and subsequent incubation with fibri-
nogen (500 mg mL1), anti-thrombin-III (50 mg mL1) and
heparin (60 mg mL1) for 1 h at RT. The plates were then washed
and stored with 2.0% (w/v) powdered milk in PBS overnight at
4 1C. Control groups included wells that were coated with
heparin (70 mg mL1; positive control) or BSA (1.0 mg mL1;
negative control) in PBS, overnight at 4 1C. Surface-modified
wells were then exposed to various concentrations of SDF-1a
(0–20 mg mL1) for 1 h and relative levels of SDF-1a binding were
measured using rabbit anti-SDF-1a (Abcam; Cambridge, USA),
HRP-conjugated goat anti-rabbit and TMB substrate. A minimum
of n = 3 was used for all ELISAs.
2.6 SDF-1a release from fibrin matrices
Release of soluble SDF-1a from fibrin matrices was conducted
as described previously.30 In short, fibrin gels were generated
with fibrinogen (3 or 25 mgmL1), human thrombin (5 UmL1),
human FXIIIa (2.5 U mL1), calcium chloride (5 mM) and
SDF-1a (500 ng mL1) in TBS. The fibrin matrices (150 mL)
were polymerized (by combining separate fibrinogen and
thrombin solutions) for 1 h at 37 1C under sterile conditions
in ultra-low binding 24-well plates. After the polymerization,
700 mL of TBS (with 0.1% w/v BSA) was added to initiate the
release assay. The release buffer was extracted, stored in 80 1C
and replaced with fresh TBS every 24 h for 7 days. On day 7, the
fibrin matrices were digested with plasmin (0.5 U mL1) to
quantify the remaining SDF-1a. A control group consisted of
soluble SDF-1a (500 ng mL1) where 30 mL was extracted for
every timepoint and also underwent the plasmin treatment.
SDF-1a content was determined via SDF-1a ELISA. All groups
were measured in triplicates.
2.7 Release assay from SDF-1a-loaded NPs embedded in fibrin
Fibrin gels (3, 10, 25 mg mL1) were formed using the same
procedure as above where free SDF-1a was replaced by PLGA
NPs (blank and SDF-1a-loaded NPs) with a final concentration
of 1 mg PLGA NPs per 1 mL of fibrin gel. Similar to the previous
release assay, fibrin matrices (150 mL) were formed in ultra-low
binding 24-well plates for 1 h at 37 1C under sterile conditions,
after which 700 mL of TBS (with 0.1% w/v BSA) was added. The
release media was extracted, replaced and stored at hours 1, 3,
6, 12, 24 48 and 72 after initiating the release assay. SDF-1a
content in all timepoints were quantified via ELISA. A 500 ng mL1
SDF-1a group as served as the control groups, where similar to
before, 30 mL was extracted at every timepoint. All groups were
tested in triplicates.
2.8 Physical characterization fibrin/NP composites
Fibrin polymerization was monitored with time-dependent optical
density measurements (Epoch; Biotek; Winooski, USA). Control
(native fibrin clots with no NPs) and NP-embedded gels (0.1, 1 &
10 mg mL1) were prepared using the same parameters as men-
tioned earlier. Three different fibrinogen (3, 15 & 30 mg mL1)
groups were tested where optical density (OD) was measured every
30 s for 2 h in triplicate per group. Terminal clot turbidity refers to
the OD at the end of 2 h.
Percent clottable protein was quantified for control and
experimental fibrin gels (with NPs; 0.1, 1 & 10 mg mL1;
n = 3). The fibrinogen content before polymerization was
compared to the remaining soluble fibrinogen that remained
following fibrin gel formation (40 min).37 Fibrinogen (FBN)
content in the remaining solution (clot liquor), taking into
account the presence of additional enzymes, was measured
using BCA where percent clottable protein (CP) is defined as the
following:
CP ð%Þ
¼ 100 FBNInitial ðmg mL
1Þ  FBNClot Liquor ðmg mL1Þ
FBNInitial ðmg mL1Þ
 
The mechanical properties of the fibrin gels were also analyzed
with an oscillatory parallel-plate geometry rheometer (MCR 101;
Anton Paar; Ashland, USA). Fibrin clots (3 & 30 mg mL1) with
and without NPs (0.1, 1, 10 mg mL1) were generated with
identical protocols as described above. The fibrin gels (0.4 mL)
were polymerized within a 400 mm gap between the top and
bottom plates (1 h at 37 1C under high humidity). A strain
sweep (0.01 to 100%) was performed to determine the linear
viscoelastic regime for all concentrations of fibrin and strain
amplitude of 1% was chosen for all subsequent frequency
sweep tests (0.01–100 Hz) to determine storage (G0) and loss
(G00) modulus (n = 2).
2.9 Statistics
Statistical analysis was performed on all quantitative assays. All
results are depicted as the mean  one standard deviation,
unless otherwise stated. Statistical analyses (GraphPad Prism,
La Jolla, CA) evaluated differences between groups using ana-
lysis of variance (ANOVA) followed by Tukey post hoc tests to
determine statistical significance with p o 0.05 considered
significant. Multiplicity adjusted p-values are reported for
Tukey post hoc comparisons.
3. Results and discussion
3.1 Characterization of SDF-1a loaded NPs
SDF-1a was successfully encapsulated in PLGA NPs using a
double emulsion method. Characterization assays included
size analyses via SEM micrographs, total protein encapsulation
efficiency as well as quantification of SDF-1a release profile
(Fig. 1). Resulting NPs were spherical in shape and had smooth
surface morphology with an average diameter ( standard error
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of mean; SE) of 288.9  19.2 nm, comparable to previously
reported PLGA NPs.32,38 The reported average NP diameter was
an average of 5 separately prepared batches. The NP population
distribution for each batch consistently ranged between 100–
1500 nm with 90% of the NPs falling within 200–600 nm
(Fig. 1C). NP size distributions were statistically consistent
between batches andNP yields ranged between 57–65%, indicating
minimal batch-to-batch variability. The total protein (BSA + SDF-1a)
encapsulation efficiency for the resulting NPs was 61.7%  2.8%.
Attempts to determine SDF-1a loading using conventional methods
requiring dissolution of NPs in an organic solvent followed by
protein extraction and quantification via SDF-1a ELISA proved
unreliable due to protein denaturation and degradation; this
issue was also previously reported by Cross et al.20 As a result, we
estimated total encapsulated SDF-1a via cumulative values from
the SDF-1a ELISA release profile (Fig. 1D). SDF-1a content
measured during the release assay amounted to a total SDF-1a
loading capacity of 293 ng of SDF-1a/1 mg of PLGA (i.e. 0.029 
0.00076% (w/w) PLGA NPs). Furthermore, the NPs exhibited a tri-
phasic release profile, frequently observed in PLGA-based release
devices.22 We observed sustained release of SDF-1a for 60 days
following an initial burst release and a lag phase approximately
between days 2 and 6 (Fig. 1D). In the first day, the NPs release
67 ng SDF-1a for every 1 mg of PLGA NPs, which translates to a
23% burst of total released SDF-1a as determined by ELISA.
PLGA-based release devices are unique since cargo release
rate is largely controlled by polymer degradation rate and thus
is not purely diffusion-mediated.22 The release profile is a result
of various interactions (i.e. cargo/polymer, cargo/cargo etc.) and
release mechanisms (i.e. diffusion, bulk erosion etc.) that are
relevant to a particular set of particles.9 After the burst release,
the mechanism of release for hydrophilic proteins is attributed
to the formation, dilation and coalescence of nano-pores (forming
mesopores) inside the PLGA matrix.40 The effective protein diffu-
sivity is directly correlated to the properties of the pore network
and protein/polymer interactions.39 Thus prolonged release in the
later stages is mediated by polymer degradation and erosion as
well protein diffusion. As a result, choice of PLGA was a rational
decision considering our goal for achieving long-term, sustained
and bioactive SDF-1a release.
Previous studies demonstrated the feasibility of encapsulating
and releasing bioactive SDF-1a (as tested by in vitromesenchymal
stem cell migration) from PLGA microparticles to achieve con-
trolled release over 40–70 days.19,20 However, both studies report
relatively low SDF-1a loading. The PLGA microparticles in one
study indicated a loading capacity of approximately 0.0018%
(w/w) of PLGA, whereas the other had a theoretical maximum
of 0.002% (w/w) SDF-1a relative to PLGA polymer. A low loading
capacity equates to a requirement of high amounts of PLGA.
Thus achieving adequate, therapeutic levels of SDF-1a may con-
flict with the accumulation of acidic byproducts that affects the
local pH.41 In comparison, we report PLGA nanoparticles with
loading capacities of SDF-1a an order of magnitude higher at
0.029% (w/w) PLGA. Additionally, we achieved SDF-1a controlled
release for 60 days, meeting our initial design criterion (Fig. 1D).
3.2 NPSC migration assays indicate release of bioactive
SDF-1a
Modified-Boyden chamber migration assays were utilized to
measure functional SDF-1a bioactivity (Fig. 2A and B). SDF-1a is
known to elicit a biphasic migratory response in vitro with a
number of cell types (NPSCSs, mesenchymal stem cells; MSCs,
leukocytes, hematopoietic cells etc.) over a wide range of con-
centrations (10–1000 ng mL1).34,42–46 This biphasic migratory
response reportedly relates to the internalization of CXCR4
upon interaction with SDF-1a. Overstimulation from high
concentrations of SDF-1a may lead to desensitization to the
chemokine.42,47 In our hands, the maximal NPSC migration
response occurred at 250 ng mL1 after 24 h and revealed a
biphasic relationship to SDF-1a concentration where 1000 ngmL1
did not elicit any chemotactic response above the basal media
levels (Fig. 2B). The biphasic response of SDF-1a on NSCs suggests
Fig. 1 SDF-1a NP characterization: (A and B) representative SEM images of SDF-1a loaded NPs depicting smooth, spherical particles; scale bars = 2 mm.
(C) Histogram illustrating the size distribution of NPs with a range between 100–1500 nm and where 90% of the population is between 200–600 nm in
diameter. (D) In vitro release assay measured with SDF-1a ELISA demonstrated sustained SDF-1a release for 60 days. The inset illustrates the initial burst
release of 23% of total measured SDF-1a within the first 24 h.
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control over SDF-1a dosage and its temporal concentration profile
is required to achieve a desired biological response.
TheW/O/W double emulsion synthesis for PLGA NPs inherently
involve harsh conditions such as water–oil interfaces, ultrasonica-
tion, freeze thaw cycles and lyophilization, known to affect the
structural integrity and the biological properties of proteins.48
Additionally, detection of SDF-1a via ELISA does not necessarily
equate to functional bioactivity since the epitope recognition site
for ELISA can vary from the biologically relevant site(s). As a result,
the Boyden chamber assay described above was used to measure
functional bioactivity of SDF-1a encapsulated in and released from
the NPs. For each time interval (day 0–1 & days 20–22), 250 ngmL1
SDF-1a and 0 ng mL1 served as the positive and negative controls
for NPSC chemotaxis, respectively. In addition, release media from
blank NPs were used as a control for confounding affects from
PLGA degradation products.
The release media from day 0–1 elicited a robust migratory
response that was significantly higher than both the negative
control (no SDF-1a; p = 0.0007) and the blank NP group (Fig. 3A
and B; p = 0.0201). No adverse effects on NPSC chemotaxis were
observed with the blank NP group for the 24 h incubation
period, agreeing with previously published results with MSCs.20
The data suggests that bioactivity of SDF-1a is not significantly
altered with the NP synthesis protocol. The day 0–1 release
media is largely composed of the burst phase that accounts for
loosely adsorbed SDF-1a on the NP surface that diffuse out
rapidly upon particle hydration. However, preservation of protein
bioactivity in the first day does not indicate sustained release of
bioactive protein. Local pH within the particles have been
reported to be opH 3 and during release, the cargo can
undergo aggregation, non-reversible adsorption and degrada-
tion leading to further loss in bioactivity and incomplete
release.48 Thus release media from day 20–22 was also evaluated
to validate maintenance of bioactive SDF-1a (Fig. 3A and C). Here,
NPSC migration significantly increased in the SDF-1a-loaded NP
group relative to blank NPs, which controlled for potential con-
founding affects from the acidic PLGA degradation products
( po 0.05). A similar trend was observed in the pairwise compar-
ison to the negative control, though not statistically significant
( p = 0.0599). In summary, encapsulation of SDF-1a in the NPs
maintained the long-term bioactivity of SDF-1a. Moreover, encap-
sulated cargo is insulated from biological proteolytic factors in
future in vivo applications. Thus we postulate this device has the
potential to improve SDF-1a half-life (25 min in blood) as shown
with other proteins in vitro and in vivo.17,48
3.3 Protein–protein interactions between SDF-1a and
fibrin(ogen)
The high burst release from the NPs within the first hours is
a concern considering biphasic response to SDF-1a (i.e.
decreased NPSC migration; Fig. 2). Moreover, high SDF-1a
concentrations in vivo reportedly initiate systemic immune cell
recruitment and infiltration.49 Modest decrease of NP burst
release magnitude may be achieved through alterations of the
NP formulation parameters.50,51 However, changes in synthesis
conditions create complex, multifaceted interactions that affect
several particle properties at once. For example, changing
polymer concentration not only affects encapsulation efficiency
and loading capacity, but it also influences particle size and
porosity, key factors determining release rate and duration.51,52
Therefore, we pursued a composite system as it affords the
ability to independently tune the release profile without com-
promising the desired attributes already attained by the NPs
(sustained release of bioactive SDF-1a).
Composite biomaterials with drug carriers embedded in
hydrogels has been explored for a number of applications.53–55
One relevant example includes basic fibroblast growth factor
(bFGF)-loaded nanoparticles embedded in fibrin to achieve
tunable, zero-order release with the ability to reduce/eliminate
the burst phenomenon.55 The presence of heparin-like binding
domains in the structure of native fibrin and its monomer,
fibrinogen, is correlated to specific binding with highly basic,
heparin-binding proteins such as bFGF, vascular endothelial
growth factor (VEGF), placenta growth factor-2 (PlGF-2) and
insulin-like growth factor-binding protein-3.30,31,56 Due to the
similarities in molecular weight, isoelectric point and heparin
binding capacities between known fibrin-binding proteins such
as, bFGF, and SDF-1a, we probed the existence of fibrin(ogen)/
SDF-1a interactions.
Fibrin(ogen)/SDF-1a interactions were determined using
three modified ELISAs that probed both fibrin/fibrinogen affi-
nity as well as, mechanistic competition with soluble heparin
(Fig. 4). First, the fibrinogen binding assay consisted of inves-
tigating soluble fibrinogen binding to adsorbed soluble factors
Fig. 2 Soluble SDF-1a elicits a biphasic migration response in a Boyden
chamber assay. (A) Schematic depicting the Boyden chamber setup where
cells that were seeded in the top chamber migrates to reach the bottom
side through chemotactic migration after 24 h. (B) NPSC chemotactic
migration demonstrates a biphasic response where the 250 ng mL1 group
is significantly different compared to both to baseline and 1000 ng mL1
SDF-1a group (* represents p o 0.05 relative to 0 ng mL1 SDF-1a; $
represents p o 0.05 relative to 250 ng mL1).
Paper Journal of Materials Chemistry B
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
3/
11
/2
01
5 
21
:3
6:
53
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 J. Mater. Chem. B, 2015, 3, 7963--7973 | 7969
(BSA, negative control; bFGF, positive control; or SDF-1a).
The results demonstrated a significant increase in fibrinogen
binding/retention on SDF-1a-coated wells relative to BSA-coated
wells (Fig. 4A and B; p o 0.05). More importantly, the
Fig. 3 Bioactive SDF-1a released from NPs. (A) Release media from day 0–1 and 20–22 were evaluated for bioactivity via NPSC chemotaxis assay.
(B) Chemotactic response from NPSCs incubated with release media from day 0–1. SDF-1a-loaded NPs (‘SDF NP’) elicits a significant increase in nuclei
count relative to both blank NPs and the negative control. (C) NPSC migration in response to release media from days 20–22. Although SDF-1a-loaded
NPs were able to increase nuclei count significantly relative to blank NPs, the difference was not statistically significant in comparison to the negative
control (* & ** represents p o 0.05 and p o 0.001 respectively, relative to negative control and $ represents p o 0.05 relative to blank NPs).
Fig. 4 Specific protein–protein interactions exist between SDF-1a and fibrin(ogen). (A) Schematic depicting fibrinogen binding assay that consisted of
high-binding ELISA plates coated with the soluble factors, bovine serum albumin (BSA; negative control), bFGF (positive control) and SDF-1a ELISA setup
used to measure fibrinogen binding affinity. (B) Signal from SDF-1a coated wells were significantly higher compared to negative controls (BSA) and
comparable to the positive control (bFGF) suggesting a specific interaction between SDF-1a and fibrinogen. (C) Increase in signal from fibrinogen binding
is attenuated for bFGF and SDF-1a-coated wells in a dose-dependent manner due to competition from soluble heparin. In contrast, BSA-coated wells do
not exhibit heparin-dependant change in signal. (D) ELISA designed to probe fibrin interactions with SDF-1awhere high-binding ELISA plates were coated
with a thin layer of fibrin, BSA (negative control), and heparin (positive control). (E) A concentration-dependent increase in signal was observed for the
fibrin-coated wells, similar to the trend observed for the positive control suggesting SDF-1a interactions persist in the polymerized form of fibrinogen,
fibrin (** represents p o 0.001 relative to negative BSA control).
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fibrinogen retention levels for SDF-1a were comparable to the
positive control bFGF-coated wells, suggesting a binding inter-
action between SDF-1a and fibrinogen (Fig. 4A and B).
The second ELISA assay probed the mechanism of SDF-1a/
fibrinogen interaction. The heparin-like binding domain in
fibrinogen is located in the first 66 amino acid residues of
the Bb chain.30,57 The high concentration of arginine and lysine
residues in that region allows promiscuous binding to both
soluble factors and heparin.30 Thus, a competition ELISA
was performed where known amounts of soluble heparin
(0.75–200 mg mL1) was added to compete with the heparin-
like binding domains on fibrinogen. The results indicate signi-
ficant attenuation of signal with increasing heparin concentration
for both bFGF and SDF-1a-coated plates (Fig. 4C). Conversely,
signal from the BSA-coated wells do not exhibit a similar depen-
dence on heparin content. The trends observed in Fig. 4B and C
agree with data from similar assays reported for other known
fibrin-binding proteins.30 Thus, the observed fibrinogen/SDF-1a
interaction cannot be attributed to non-specific interactions, but
most likely due to specific SDF-1a/fibrinogen interactions via the
heparin-binding domain.
The final ELISA probed SDF-1a interactions with the
insoluble, polymerized fibrin after a thin layer was deposited
on ELISA plates.36 Concentration dependent retention of SDF-1a
on both, heparin-coated (positive control) and fibrin-coated wells
relative to BSA-coated negative controls, indicate that specific
SDF-1a/fibrinogen interactions are maintained when fibrinogen
polymerizes to form fibrin (Fig. 4D and E). Collectively, the
results from these modified ELISA assays indicate specific
protein–protein interactions between SDF-1a and fibrin(ogen)
exists primarily via SDF-1a interactions with the heparin binding
domain.
3.4 Fibrin sequesters free SDF-1a
Affinity-based interactions via the heparin-like binding domains
on fibrin(ogen) is hypothesized to play a major role in deter-
mining growth factor release profile. For example, soluble
heparin binding factors such as PlGF-2, bFGF and VEGF exhibit
prolonged release and sequestration in native fibrin matrices
while, VEGF121 (isoform lacking the heparin-binding domain)
and NGF are released in a more diffusion-limited manner.24,30,31
Although fibrin density, fiber length and fiber aspect ratio are
important determinants of release profile, evidence of immobi-
lization/sequestration (slow or no protein release) is a key indi-
cator for affinity-based interactions playing a dominant role in
determining release rate. For example, PlGF-2-loaded fibrin gels
releaseB15% of cumulative cargo in the first 2 days, whereas the
remaining cargo was sequestered in the fibrin matrix for at least
7 days.30 In contrast, NGF (low fibrinogen binding affinity)
encapsulated in an identical fibrin matrix exhibited 100% cumu-
lative release within 2 days.30 Additionally, Wong et al. reported a
similar release profile for bFGF and concluded that diffusion-
only release mechanism cannot account for cargo sequestration
observed.31
Building on the SDF-1a-fibrin(ogen) ELISA assays (Fig. 4), we
conducted SDF-1a release assays from fibrin gels to evaluate
ability of the protein–protein interactions to sequester SDF-1a
within three-dimensional fibrin matrices. We also evaluated
the effects of fibrin density on SDF-1a release profile with the
hypothesis that altering the number of available binding sites
will dictate the maximal amount of sequestered SDF-1a within
fibrin matrices.58 We must note that altering fibrin density also
modifies various matrix morphological properties and thus
diffusion-limited cargo release profile; however, our experi-
ment was designed to focus specifically on the sequestration
of SDF-1a within a short 7 day release period (Fig. 5). Thus, two
concentrations of fibrin were evaluated, 3 mg mL1 (physio-
logically relevant concentration) and 25 mg mL1 gels loaded
with a constant mass of SDF-1a (500 ng mL1). The release
study indicates that 90% of the encapsulated SDF-1a was
released after 2 days in the 3 mg mL1 group whereas only
20% of the SDF-1a was released from the 25 mg mL1 group
within that same time frame (Fig. 5A). More interestingly, SDF-
1a release between days 2–7 was undetectable using ELISA,
suggesting sequestration of residual SDF-1a not immediately
released within the first 2 days. After 7 days, fibrin clots were
Fig. 5 SDF-1a sequestered in fibrin matrices. (A) Release profile of free SDF-1a was significantly altered by encapsulation in different densities of fibrin.
The 25 mg mL1 group showed a release of 20% after 2 days, with no detectable SDF-1a released up to day 7. In contrast, the 3 mg mL1 released 90% of
its cargo within the first 2 days. (B) To ensure that the differences seen in the release profile were not due to problems with SDF-1a detection, the fibrin
matrices were digested using plasmin and the total protein detected was similar to the initial payload for both groups.
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digested with plasmin, a serine protease, to liberate immobilized
SDF-1a for quantification. Cumulative detection of released SDF-
1a in combination with SDF-1a recovered after fibrin digestion
was similar to the initial payload for both groups (Fig. 5B). Thus,
the plateau in the SDF-1a release profile after the first 2 days
strongly suggests that SDF-1a was captured and sequestered in
fibrin matrices. The amount of SDF-1a sequestered was propor-
tional to fibrin density as expected, where the 3 mg mL1 group
was only able to sequester roughly 10% of the encapsulated SDF-
1a. Additionally, The SDF-1a release profile from fibrin was
Fig. 6 Magnitude of burst release from SDF-1a-loaded NPs was modulated with fibrin. (A) SDF-1a release from first three days was significantly altered
by embedding NPs in different concentrations of fibrin. After 24 h, the 25 mg mL1 group was able to reduce SDF-1a detected in the release media by
60% relative to free NPs. (B) Total SDF-1a detected was significantly different between the free NPs and 10 mg mL1, as well as the 10 and 25 mg mL1
groups. Although the total SDF-1a detected after 72 h in the 3 mg mL1 group was not significantly different, at 24 h cumulative SDF-1a dosage is
decreased by 15.8% in the fibrin group (* represents p o 0.05 relative to free NPs; $ represents p o 0.05 relative to 25 mg mL1 fibrin group).
Fig. 7 NP encapsulation does not significantly affect fibrin clot properties. (A) Percent clottable protein is not a function of NP encapsulation (up to
10 mg mL1). Presence of NPs do not affect the ability of fibrinogen to interact with other monomers to form the insoluble fibrin clot. (B) Terminal
turbidity of fibrin clots is not affected by NP concentrations up to 10 mg mL1. The increase in turbidity seen in the 3 mg mL1 fibrinogen group with
10 mg mL1 NPs is likely due to the presence of the NPs themselves. (C) Storage (G0) and loss (G00; dotted plots) moduli of 3 mg mL1 (green) and
30 mg mL1 (red) fibrin clots. Native fibrin (no NPs) and fibrin with 10 mg mL1 NP illustrate that the presence of NPs cause minimal changes in fibrin
mechanical properties. (D) Overall strength of 3 mg mL1 fibrin gels are not a function of NP content. Although 30 mg mL1 gels did show significant
differences at 1 & 10 mg mL1 NP groups, two-way ANOVA analysis indicates NPs do not play a statistically significant role in fibrin storage modulus
(p = 0.086) (* represent p o 0.05 relative to 30 mg mL1 fibrin with 0 mg mL1 NPs).
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comparable to previously reported for release kinetics for soluble
bFGF from fibrin.30,31
3.5 Fibrin modulates SDF-1a burst release from PLGA NPs
Given the interaction uncovered between SDF-1a and fibrin(ogen),
we evaluated potential modulation of NP release profile. Specifi-
cally, we aimed to determine the effect of embedding SDF-1a-
loaded NPs in different fibrin densities on the burst release in an
idealized in vitro release assay. This experiment only focused on
the first 72 h to fully capture the kinetics of the burst phenomena.
The same concentration of NPs (1 mg of PLGA/1 mL of fibrin) was
embedded within three different fibrin clot densities (3, 10 &
25 mg mL1). The resulting SDF-1a release profiles were strongly
dependent on the fibrin concentrations (Fig. 6A). Specifically, NPs
embedded in 25 mg mL1 clots reduced the amount of detected
SDF-1a byB55% after 24 h compared to NPs freely suspended in
buffer. The total cumulative released SDF-1a was significantly
reduced in the 10mgmL1 ( po 0.01) and 25mgmL1 ( po 0.01)
groups after 72 h in comparison to free NPs (Fig. 6B). Additionally,
difference in total protein released between the 25 mg mL1, and
both 3 mg mL1 ( p o 0.01) and 10 mg mL1 ( p o 0.01) groups
was also statistically significant. Although, total SDF-1a detected in
the 3 mg mL1 group was not significantly different (compared to
free NPs) after 72 h, cumulative SDF-1a dosage was 15.8% lower
after the first 10 h upon addition of fibrin. Therefore, these data
suggest the following, (1) amplitude of the NP burst may be tuned
by exploiting SDF-1a/fibrin interactions and (2) embedding the NPs
within fibrin gels of varying concentrations controls the amount of
SDF-1a released within the first 72 h in vitro, under idealized
conditions.
3.6 PLGA NPs do not significantly alter fibrin polymerization
Fibrin (with and without NPs) matrices were assessed bymeasuring
clottability of fibrinogen monomer, end-point turbidity and rheo-
logical characterization of viscoelastic properties. Our data suggests
that the presence of NPs (up to 10 mg mL1) does not significantly
disrupt the formation of fibrin (Fig. 7A). As a result, end-point
turbidity of fibrin clots were also similar between native and
NP-embedded gels for the 15 & 30 mg mL1 fibrin groups
(Fig. 7B). The differences observed for the 3 mg mL1 group was
due to the presence of the NPs themselves (data not shown).
Rheological studies further supports that fibrin clot integrity
was maintained upon addition of NPs (Fig. 7C and D). The
low-frequency plateau in the storage modulus (G0) of both 3 &
30 mg mL1 fibrin groups indicate polymerization of fibrinogen to
form viscoelastic fibrin (Fig. 7C).59 Additionally, the overall char-
acteristics of the storage and loss moduli was not altered upon
adding 10 mg mL1 NPs in either 3 or 30 mg mL1 fibrin matrices
(Fig. 7C). The overall strength of fibrin was not dependent on NP
content for the 3 mg mL1 fibrin group. Although statistically
significant changes inG0 was observed for 30mgmL1 fibrin group
with 1 & 10 mg mL1 NP (Fig. 7D), the two-way ANOVA indicates
that overall, NP concentration is not a significant determinant of
fibrin storage modulus ( p = 0.086). Overall values for G0 acquired
for the fibrin groups were similar to other reports in literature for
native fibrin.59–61
4. Conclusion
Here, we report successful encapsulation of SDF-1a within
PLGA NPs to achieve controlled release over 60 days. Functional
bioactivity of encapsulated and released SDF-1a was demon-
strated through in vitro NPSC chemotactic migration assays.
However, careful control over time-dependent SDF-1a concen-
tration is crucial in eliciting desired therapeutic outcome. We
determined that SDF-1a was successfully sequestered in fibrin
clots and that NPs embedded in different concentrations of
fibrin controlled the magnitude of the burst release profile
without negatively affecting fibrin matrix properties. These
results are significant in potentially obtaining local and sus-
tained release of SDF-1a in a neural injury site to amplify and/or
sustain NPSC-mediated endogenous repair response.
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